Propanc Biopharma Approves Reverse Stock Split to Preserve Nasdaq Listing
PPCB is trading near its 52-week low of $0.46 (0.3% above the low) on light trading volume (0.1× avg).
Summary
Propanc Biopharma's board approved a reverse stock split between 1:2 and 1:10, reducing outstanding shares from ~10.33M to between ~5.17M and ~1.03M. Majority holder James Nathanielsz (63.56% voting power) consented in writing; effectiveness awaits Nasdaq approval.
Key Events · Corporate Governance and Compliance · PPCB
-
Reverse Stock Split Approved
On October 6, 2026, the board approved a reverse split at a ratio between 1:2 and 1:10, reducing outstanding shares from approximately 10,331,116 to between 5,165,558 and 1,033,112 shares.
-
Majority Stockholder Consent
James Nathanielsz, holding 1,400,000 common shares and 1 Series B preferred share (63.56% voting power), approved the split by written consent in lieu of a meeting.
-
Nasdaq Compliance Motivation
The company states the split is necessary to maintain financing and capital-raising ability, with effectiveness contingent on Nasdaq processing and approval.
-
Distress Context
This follows a going-concern warning, material weaknesses, and an $18.9M net loss disclosed in the September 25, 2026 10-K, and a prior reverse split executed May 18, 2026.
Analysis · PPCB · Life Sciences
To maintain its financing and capital-raising ability, Propanc Biopharma's board approved a reverse stock split at a ratio between 1:2 and 1:10, with majority stockholder James Nathanielsz (63.56% voting power) consenting in writing. The split would reduce outstanding shares from approximately 10.33 million to between 5.17 million and 1.03 million shares. Effectiveness is contingent on Nasdaq approval. This move comes amid a going-concern warning, material weaknesses, and an $18.9M net loss disclosed in the September 25, 2026 10-K, and follows a prior reverse split executed May 18, 2026. The stock trades near its 52-week low of $0.46, and the split is aimed at boosting the share price to regain compliance and attract capital.
How filings like this one have moved
In the 30 days to Oct 8, 2026, 36.3% of the 1065 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PPCB was trading at $0.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.6M. The 52-week trading range was $0.46 to $49.25. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.